Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Sanara MedTech (SMTI) EPS (Weighted Average and Diluted) (2016 - 2025)

Sanara MedTech (SMTI) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with -$3.4 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) fell 16900.0% year-over-year to -$3.4, compared with a TTM value of -$4.54 through Sep 2025, down 577.61%, and an annual FY2024 reading of -$1.14, down 119.23% over the prior year.
  • EPS (Weighted Average and Diluted) was -$3.4 for Q3 2025 at Sanara MedTech, down from -$0.23 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.02 in Q3 2024 and bottomed at -$3.4 in Q3 2025.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.48, with a median of -$0.23 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 94.12% in 2023, then crashed 16900.0% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.51 in 2022, then soared by 94.12% to -$0.03 in 2023, then crashed by 1566.67% to -$0.5 in 2024, then plummeted by 580.0% to -$3.4 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for SMTI at -$3.4 in Q3 2025, -$0.23 in Q2 2025, and -$0.41 in Q1 2025.